Klaasen et al. reported a relationship between a high visfatin level and an increased atherogenic index in adalimumab-treated RA patients and suggested that visfatin reduction can lead to decreased cardiovascular risk independent of disease activity [6]. This evidence concerns the gene NAMPT and rheumatoid arthritis.